← Back

Tonghua Dongbao Pharmaceutical Co Ltd

Tonghua Dongbao Pharmaceutical Co., Ltd. is a China-based company that, along with its subsidiaries, researches, develops, produces, and sells biological products, traditional Chinese medicines, chemical medicines, and other drugs in China and internationally. Its product portfolio includes liraglutide, insulin glargine, insulin aspart, human insulin, and various insulin injections, as well as oral anti-diabetic drugs such as sitagliptin phosphate, repaglinide, and engagliflozin. The company also offers insulin pens and pen needles, a Chronic Disease Management Platform for diabetes, and engages in activities ranging from plastic building materials to real estate and pharmaceutical retail. Founded in 1985, it is headquartered in Tonghua, China.

Price · split & dividend adjusted
News & notes moving 600867.CG
China
600867.CG

Tonghua Dongbao Releases 2026 Interim Report with Net Profit of 296 Million Yuan

Tonghua Dongbao released its 2026 interim report on August 25, 2026. Total operating revenue was 1.553 billion yuan, net profit attributable to the parent company was 296 million yuan, and net cash inflow from operating activities was 533 million yuan. The latest asset-liability ratio was 12.95 percent, up 0.69 percentage points from the previous quarter. The latest gross margin was 70.79 percent, down 0.83 percentage points from the previous quarter and down 0.66 percentage points from the same period last year. The latest return on equity was 4.33 percent, and diluted earnings per share was 0.15 yuan. The latest total asset turnover was 0.20 times, inventory turnover was 0.66 times, the number of shareholders was 114,700, and the top ten shareholders held 939 million shares, accounting for 47.96 percent of total share capital.
Tonghua Dongba…
600867.CG · Capital · Neutral Interim report shows net profit of 296 million yuan, but no comparative expectations or market reaction provided.
Read original ↗
Jiemian·42dRead more →
China
600867.CG▼

Tonghua Dongbao terminates THDBH110 capsule development project and records impairment

Tonghua Dongbao has decided to terminate the THDBH110 and THDBH110 capsule development project, and will fully record an asset impairment provision for the capitalized development costs of the project, totaling 16.8854 million yuan. The impairment will reduce the company's total profit for the first half of 2026 by 16.8854 million yuan.
Tonghua Dongba… ▼
600867.CG · Capital · Negative Termination of THDBH110 project and impairment of 16.8854 million yuan reduces first-half 2026 profit.
Read original ↗
CLS·43dRead more →
China
600867.CG▲2

Tonghua Dongbao's first-half 2026 net profit attributable to parent rises 37.32% year on year

Tonghua Dongbao released its 2026 semi-annual report, during which it achieved operating revenue of 1.553 billion yuan, up 11.13% year on year; net profit attributable to shareholders of the listed company was 296 million yuan, up 37.32% year on year.
Tonghua Dongba… ▲
600867.CG · Capital · Positive Net profit attributable to parent rises 37.32% year on year in H1 2026.
Read original ↗
央广财经·43dRead more →
China
600867.CG▲3

Tonghua Dongbao first-half net profit attributable to parent 296 million yuan, up 37.32% year on year

Tonghua Dongbao released its 2026 interim report. Operating revenue was 1.552 billion yuan, up 11.13% year on year. Net profit attributable to the parent was 296 million yuan, up 37.32% year on year. Net profit attributable to the parent after deducting non-recurring items was 296 million yuan, up 35.55% year on year. Net operating cash flow was 533 million yuan, up 62.42% year on year. Second-quarter operating revenue was 805 million yuan, up 11.5% year on year, and net profit attributable to the parent was 169 million yuan, up 55.5% year on year. The company said sales of insulin analogue products grew significantly, driving higher domestic sales revenue. Market access and sales volume for products such as insulin glargine and insulin aspart continued to increase. At the same time, through cooperation with Huisheng Biotech, it introduced insulin degludec and insulin aspart injection, and multiple products received overseas marketing approval.
Tonghua Dongba… ▲
600867.CG · Capital · Positive First-half net profit up 37.32% year on year, driven by strong sales of insulin analogues.
惠升生物 · Demand · Positive Cooperation with Tonghua Dongbao introduced insulin degludec and insulin aspart injection, expanding market access.
Read original ↗
财中社·43dRead more →
China
600867.CG▼

Tonghua Dongbao's controlling shareholder releases and re-pledges 32 million shares, cumulative pledge exceeds 90% of holdings

Tonghua Dongbao's controlling shareholder, Dongbao Group, carried out a release-and-re-pledge operation involving 32 million shares. According to an August 12 announcement, Dongbao Group released the pledge on 32 million shares, representing 5.17% of its holdings and 1.63% of the company's total share capital, while simultaneously re-pledging the same number of shares. As of the announcement date, Dongbao Group's cumulative pledged shares reached 582 million shares, accounting for 93.94% of its holdings and 29.71% of the company's total share capital. In the first quarter of 2026, the company achieved revenue of 748 million yuan and net profit attributable to the parent company of 127 million yuan.
Tonghua Dongba… ▼
600867.CG · Capital · Negative Controlling shareholder pledges 93.94% of holdings, signaling financial strain and potential share overhang.
Read original ↗
财中社·55dRead more →
600867.CG▼

Tonghua Dongbao's Controlling Shareholder Releases and Re-pledges 33 Million Shares, Cumulative Pledge Ratio Hits 93.94%

Tonghua Dongbao's controlling shareholder, Dongbao Group, released 33 million pledged shares on July 27, 2026, and simultaneously re-pledged the same number of shares. As of the announcement date, Dongbao Group's cumulative pledged shares stood at 582 million shares, accounting for 93.94% of its total holdings and 29.71% of the company's total share capital. In the first quarter of 2026, Tonghua Dongbao achieved revenue of 748 million yuan and net profit attributable to the parent company of 127 million yuan.
Tonghua Dongba… ▼
600867.CG · Capital · Negative Controlling shareholder re-pledges 33M shares, cumulative pledge ratio hits 93.94%, signaling financial strain and potential risk of forced selling.
Read original ↗
财中社·70dRead more →
600867.CG▲2

Tonghua Dongbao's Co-Developed Insulin Aspart Injection Receives US FDA Approval

The insulin aspart injection co-developed by Tonghua Dongbao and Jianyou Co. has received US FDA approval for marketing. The drug is indicated to improve glycemic control in adult and pediatric patients with diabetes. According to Novo Nordisk's 2025 annual report, its insulin aspart sales in the United States were 7.166 billion Danish kroner, equivalent to approximately 1.126 billion US dollars, and global sales were 15.765 billion Danish kroner, equivalent to approximately 2.477 billion US dollars. This approval marks a significant milestone in the company's internationalization journey. In the first quarter of 2026, Tonghua Dongbao achieved revenue of 748 million yuan and a net profit attributable to the parent company of 127 million yuan.
Tonghua Dongba… ▲
600867.CG · Regulation · Positive US FDA approval for its co-developed insulin aspart injection, a regulatory milestone enabling market entry.
Read original ↗
财中社·71dRead more →
600867.CG

Tonghua Dongbao to invest up to 162 million yuan in Amoytop Biotech convertible bonds

Tonghua Dongbao plans to exercise its preemptive subscription rights to participate in the purchase of convertible corporate bonds issued by Xiamen Amoytop Biotech to non-specific investors, with an investment amount not exceeding 162 million yuan. The company holds 42.01 million shares of Amoytop Biotech, representing a 10.29 percent stake. The investment principal for this subscription accounts for 2.28 percent of the company's audited net assets for 2025 and 2.24 percent of its unaudited net assets for the first quarter of 2026. The total proceeds from Amoytop Biotech's convertible bond issuance will not exceed 1.533 billion yuan. Tonghua Dongbao classifies this investment as a financial asset measured at fair value through profit or loss, and changes in fair value will affect the company's net profit. In the first quarter of 2026, Tonghua Dongbao achieved revenue of 748 million yuan and net profit attributable to the parent company of 127 million yuan.
Xiamen Amoytop… ▲Tonghua Dongba…
688278.CG · Capital · Positive Amoytop Biotech receives up to 1.533 billion yuan from convertible bond issuance, providing capital for its operations or growth.
600867.CG · Capital · Neutral Tonghua Dongbao invests up to 162 million yuan in Amoytop Biotech convertible bonds, classified as financial asset at fair value through profit or loss; impact depends on future fair value changes.
Read original ↗
财中社·71dRead more →
© 2026 MarketIVAsset